This section contains a list of the policy recommendations of the Pan Mersey Area Prescribing Committee.
Reviews of the new medicines have been conducted by our pharmacists using a number of resources including National Institute for Health and Clinical Excellence (NICE) which is a Special health Authority (SHA) set up in 1999. It is used to give advice to the NHS on best clinical practice including the clinical and cost effectiveness of drugs and other treatments.
The Pan Mersey Area Prescribing Committee recommends the prescribing of CICLOSPORIN 1mg/mL eye drops (Verkazia®), by specialists only, for the treatment of severe vernal keratoconjunctivitis (VKC) in children from 4 years of age and adolescents.
The Pan Mersey Area Prescribing Committee does not recommend the prescribing of FLUOCINOLONE intravitreal implant (Iluvien®) for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy, in accordance with NICE TA613
The Pan Mersey Area Prescribing Committee recommends the prescribing of RANIBIZUMAB intravitreal injection (Lucentis®), by ophthalmologists only, for the treatment of visual impairment secondary to choroidal neovascularisation (CNV) in conditions not covered by NICE technology appraisals.